Newborn Screening Programmes in the United Kingdom

Size: px
Start display at page:

Download "Newborn Screening Programmes in the United Kingdom"

Transcription

1 Newborn Screening Programmes in the United Kingdom This paper has been developed to increase awareness with Ministers, Members of Parliament and the Department of Health of the issues surrounding the serious lack of funding for all the necessary work including research, literature review, economic evaluation and pilot studies, which is preventing NHS England and Public Health England timously adding appropriate disorders onto the UK newborn screening programme. We are asking Government Ministers, Members of Parliament and the Department of Health to consider the issues and recommendations outlined in this paper, with a view to requesting and supporting discussions between the Department of Health, NHS England, Public Health England and the National Institute for Health Research (NIHR) on how these issues can be addressed. There are currently a number of disorders that are being considered by the UK National Screening Committee (UK NSC) and some appropriate disorders waiting in line which are not being progressed due to these challenges. This has a direct impact on our ability to save children's lives. 1. Background to Newborn Screening in the United Kingdom In the United Kingdom (UK) we screen newborn babies for 9 congenital disorders. Screening newborns in the UK commenced with PKU in The most recent group of 4 disorders was added to the programme in England in early Early identification of babies at risk from rare disorders can offer the opportunity of immediate life saving or life enhancing treatment. Without early identification and treatment, children with inherited disorders will lead a life of disability or may die. It is a hard fact that many children in the UK do die from conditions that are not diagnosed sufficiently early. The UK Rare Disease Strategy also outlines the importance of early diagnosis for those who will subsequently present with rare disorders in early adulthood or later in life. Early identification of rare disorders can subsequently reduce costs to the NHS. Many other countries screen for more disorders than we do in the United Kingdom. Developments in medicines and new therapies enables the treatment of newborns with inherited disorders more viable. However accepting new disorders onto the UK newborn screening programme unfortunately remains a very lengthy process. In the UK we have added only 8 additional disorders to the programme since It took over 5 years to get the latest 4 disorders added to the UK programme in A comparative table of the screening position in Europe as at 2015 is attached at Annex 1. Public Health England, the UK National Screening Committee (UK NSC) and NHS England, along with most countries, have accepted the World Health Organization (WHO) criteria for determining whether a condition is suitable for adding onto the UK Newborn Screening programme. The list of criteria is outlined at the end of this document at Annex.2 The issues and recommendations contained in this paper are a result of conferences and meetings held during 2016 between the UK Patient Advocates for Newborn Screening Collaborative Group, clinicians, scientists, UK NSC representatives and other patient organisations, to address the challenges in securing more appropriate disorders onto the UK newborn screening programme. 1

2 2. UK National Screening Committee Quality Improvements During 2014, the House of Commons, Parliamentary Science and Technology Committee conducted an inquiry into health screening in the UK. Following a wide consultation exercise, including verbal submissions, a number of recommendations were made. In response to these recommendations, Public Health England and the UK NSC have made some quality improvements. Improvements include the development of new guidance for those proposing new disorders, the introduction of an annual stakeholder conference and, from September 2016, an annual open call for proposals for suitable new disorders to be considered for inclusion in the UK newborn screening programme. Anyone can submit a proposal to the UK NSC, although understandably it is unlikely to succeed without the support of expert health professionals with a knowledge of the particular disorder or group of disorders. The UK NSC has also introduced a more robust process for reviewing conditions that have previously been considered and rejected. 3. Meeting the criteria for disorders in the UK In order to meet the criteria for acceptance of a disorder onto the UK newborn screening programme and in considering a disorder, there are some key areas of work that do need to be commissioned by NHS England or Public Health England, UKNSC: Commissioning work to review the evidence presented by those submitting proposals. Also to support those submitting proposals throughout the process. Where the evidence is not available or appears insufficiently robust for the UK to identify the research questions, to commission the necessary research required to secure the required evidence or to communicate research priorities to the NIHR so it can be considered and prioritised. To undertake the necessary economic evaluation to ensure that evidence on the cost benefit and/or cost effectiveness analyses of newborn screening for a disorder has been balanced, i.e. at a reasonable cost and in relation to expenditure on medical care as a whole. This should incorporate both medical and social economic evaluation. When good quality evidence exists, to introduce pilot programmes to ensure all the newborn screening process works together. This is to ensure that all the required criteria in respect of the robustness of the test, the wider benefits of screening, the effectiveness of the screening, that screening brings positive health outcomes and the acceptability of the screening to both public and health professionals, can be determined prior to the introduction of a National screening programme. Pilot programmes are therefore crucial when introducing new disorders onto a newborn screening programme. 2

3 4. Financial and Funding Issues There are a number of financial issues that are creating a significant barrier to the consideration of new and appropriate disorders being submitted for inclusion in the UK newborn screening programme. There are complexities and concerns around the interpretation by NHS England, Public Health England and the National Institute for Health Research (NIHR) of what is 'research' and what is the 'implementation' component when considering a newborn screening pilot study. These definitions do impact how newborn screening pilot studies are funded. Although 'research' components of a pilot programme may be funded, the 'implementation' aspects of a pilot programme are considered not to be 'research'. Therefore those funding streams for research projects are not considered to be available for the 'implementation' elements of newborn screening pilots. It remains unclear what exactly the NIHR will fund and where the funding streams are to provide for the rest of the work. You will appreciate that this is certainly creating some confusion, particularly as we understand that in other areas of health the NIHR does fund 'implementation'. There is consequently a lack of clarity on who is responsible within the Department of Health for funding all the necessary work, including economic evaluation and the necessary pilot programme work. There is no tariff for newborn screening and no ring-fenced funding. There is no sense of direction on where the funding streams actually sit to move forward necessary work on newly proposed conditions. We also understand that some previously utilised funding streams for newborn screening are unavailable. We are unclear as to whether this is because newborn pilot implementation studies are not considered 'research'. Examples are the National Institute for Health Research schemes; the Collaboration for Leadership in Applied Health Research and Care (CLHARC) and Research for Patient Benefit (RfpB). Some funding streams, their scope and whether these could be utilised for newborn screening are outlined at Annex 3. Clarification is particularly critical for patients and patient organisations who are proposing new appropriate disorders for screening. It will inform what funding is available for all work, where there is a lack of funding within Public Health England or NHS England and inform whether there is a funding gap that needs to be filled from other sources. The burden of undertaking the required economic evaluation to support a proposal for newborn screening is currently resting with the proposer, i.e. the patient organisation or the charity who can ill afford what is a significant cost. Research based projects require a higher level of consent on part of participating subjects which in reality would add additional costs. In addition there are costs associated with ethical issues in consideration of appropriateness of newborn screening programmes. Recommendation 1: There needs to be in place greater clarity in definitions of all the component parts of the work required within the process of proposing and securing a new disorder onto the 3

4 UK NBS programme. There should be clarity and guidance for the proposer and other stakeholders on where the funding streams are to support each of these parts of the process. Recommendation 2: Economic evaluation should be considered to be a research question and funding for this work should within NHS England, NIHR which is the research evaluation arm of the NHS and not with proposers who are generally patient organisations supported by clinical and scientific experts. 5. Responsibilities and Guidance There is some confusion within the process on who is responsible i.e. Public Health England or NHS England, for commissioning the necessary work required, including from the National Institute for Health Research (NIHR) or elsewhere. We understand that the NIHR has competing priorities and do not have sufficient funding to do all of the NHS projects that are required. We accept that prioritisation in health is required, however there is a danger that newborn screening programmes may not being given the necessary priority. The UK Strategy for Rare Diseases in England, published in 2013 and to be implemented by 2020, contains a recommendation under 'Identifying and preventing rare diseases', that the Department of Health will continue to work with the UKNSC to ensure that the potential role of screening in achieving earlier diagnosis is appropriately considered in the assessment of all potential new national screening programmes and proposed extensions to existing programmes. Recommendation 3: The issues raised in this paper in relation to clarification and funding is a barrier to implementing the UK Strategy for Rare Diseases and therefore needs to be addressed as a matter of urgency. Stakeholders would welcome improved support and guidance when making new proposals to the UK NSC. However Public Health England (UKNSC) appear not have sufficient resources to do more to engage with, assist and support those proposing new conditions. This engagement and support becomes even more important in light of annual calls for proposals. There should be greater clarity on what support UK NSC are able to offer those submitting proposals. Recommendation 4: The UK NSC Programme Director should be sufficiently resourced to deliver necessary guidance and support services to proposers throughout the process as defined by Public Health England. This will enable them to be in a position to work alongside those proposing disorders for the newborn screening programme, ensuring that all considerations are met and work done in a collaborative manner. 6. The unreasonable burden on patients and organizations representing patients In light of the funding issues outlined, an increased burden is being put on patients and particularly organisations representing patients to secure money to commission the work that the NHS England 4

5 and Public Health England is responsible for. In some instances funding is being secured from overseas or from their own members. A recent quote to a UK patient organisation from an appropriate UK research institution to do the necessary economic evaluation work for newborn screening for a disorder affecting UK children is between 60,000 and 90,000. Patient organisations should not be 'propping up' the NHS where proposals for new disorders are being submitted. This is wholly unacceptable This situation can also present inequitable treatment for children affected by different rare conditions. A larger and better resourced patient organisation with access to international funding can sometimes find a way to financially support the commissioning of the necessary work required to move forward a proposal to the UK National Screening Committee. Others who cannot access the same funding sources are unable to progress their proposal for newborn screening. Recommendation 5: Department of Health, NHS England and Public Health England to issue clear guidelines on how screening research is funded. To publish clear avenues for funding that proposers might consider when considering submitting a proposal. Public Health England and NHS England to give clarity on what a proposer might anticipate having to fund themselves as part of the process and offer guidance on what institutions or research establishments within the UK that proposers might approach. Recommendation 6: Although we welcome the introduction of the Annual Stakeholder Conference this conference covers stakeholders from every area of public health screening in the UK. It is not sufficiently focused on or engaged with newborn screening, including engagement with stakeholders with, or representing those, with the rare disorders. We suggest that a separate dialogue and conference should be introduced for newborn screening stakeholders. Patricia A Roberts Chair of the UK Patient Advocates for Newborn Screening Group (PANS) and Director of Save Babies Through Screening Foundation UK. 30th January 2017 This paper is submitted on behalf of the PANS Group and has the support of the British Inherited Metabolic Disease Group (BIMDG). The PANS Group is a collaborative of rare disease patient organisations, all with an interest in advocating for the extension of the newborn screening programme in the UK for appropriate disorders, i.e.(agsd UK, Save Babies UK, Children Living with Inherited Metabolic Disorders (Climb), ALD Life, the MPS Society, Archangel Trust. The group is supported by relevant scientists and other health professionals. 5

6 Annex 1 Table of the position Newborn screening position in Europe has been taken from the report 'Current Status of Newborn Screening worldwide

7 Annex 2 The screening criteria is outlined below and can be accessed at the GOV.UK website. at Criteria for appraising the viability, effectiveness and appropriateness of a screening programme. 1.The condition 1. The condition should be an important health problem as judged by its frequency and/or severity. The epidemiology, incidence, prevalence and natural history of the condition should be understood, including development from latent to declared disease and/or there should be robust evidence about the association between the risk or disease marker and serious or treatable disease. 2. All the cost-effective primary prevention interventions should have been implemented as far as practicable. 3. If the carriers of a mutation are identified as a result of screening the natural history of people with this status should be understood, including the psychological implications. 2.The test 4. There should be a simple, safe, precise and validated screening test. 5. The distribution of test values in the target population should be known and a suitable cut-off level defined and agreed. 6. The test, from sample collection to delivery of results, should be acceptable to the target population. 7. There should be an agreed policy on the further diagnostic investigation of individuals with a positive test result and on the choices available to those individuals. 8. If the test is for a particular mutation or set of genetic variants the method for their selection and the means through which these will be kept under review in the programme should be clearly set out. 3.The intervention 9. There should be an effective intervention for patients identified through screening, with evidence that intervention at a pre-symptomatic phase leads to better outcomes for the screened individual compared with usual care. Evidence relating to wider benefits of screening, for example those relating to family members, should be taken into account where available. However, where there is no prospect of benefit for the individual screened then the screening programme shouldn t be further considered. 7

8 10. There should be agreed evidence based policies covering which individuals should be offered interventions and the appropriate intervention to be offered. 4.The screening programme 11. There should be evidence from high quality randomised controlled trials that the screening programme is effective in reducing mortality or morbidity. Where screening is aimed solely at providing information to allow the person being screened to make an informed choice (such as Down s syndrome or cystic fibrosis carrier screening), there must be evidence from high quality trials that the test accurately measures risk. The information that is provided about the test and its outcome must be of value and readily understood by the individual being screened. 12. There should be evidence that the complete screening programme (test, diagnostic procedures, treatment/ intervention) is clinically, socially and ethically acceptable to health professionals and the public. 13. The benefit gained by individuals from the screening programme should outweigh any harms for example from over diagnosis, overtreatment, false positives, false reassurance, uncertain findings and complications. 14. The opportunity cost of the screening programme (including testing, diagnosis and treatment, administration, training and quality assurance) should be economically balanced in relation to expenditure on medical care as a whole (value for money). Assessment against this criteria should have regard to evidence from cost benefit and/or cost effectiveness analyses and have regard to the effective use of available resource. 5.Implementation criteria 15. Clinical management of the condition and patient outcomes should be optimised in all health care providers prior to participation in a screening programme. 16. All other options for managing the condition should have been considered (such as improving treatment or providing other services), to ensure that no more cost effective intervention could be introduced or current interventions increased within the resources available. 17. There should be a plan for managing and monitoring the screening programme and an agreed set of quality assurance standards. 18. Adequate staffing and facilities for testing, diagnosis, treatment and programme management should be available prior to the commencement of the screening programme. 19. Evidence-based information, explaining the purpose and potential consequences of screening, investigation and preventative intervention or treatment, should be made available to potential participants to assist them in making an informed choice. 20. Public pressure for widening the eligibility criteria for reducing the screening interval, and for increasing the sensitivity of the testing process, should be anticipated. Decisions about these parameters should be scientifically justifiable to the public. 8

9 Annex 3: Funding streams within NHS England which could support Newborn Screening introduction: (Information current as at January 2017). Funding Source Type of Funding What it covers Can NBS work fit within this initiative or has this funding stream supported NBS initiatives in the past National Institute for Health Research NIHR Health Technology Assessment Programme HTA The HTA Programme is the largest of the NIHR programmes. HTA will fund independent research about the effectiveness, costs and broader impact of healthcare treatments and tests for those who plan, provide or receive care in the NHS. We fund our studies via a number of routes including commissioned and researcher led work streams. /hta The HTA Programme funds research about the clinical and cost effectiveness and broader impact of healthcare treatments and tests for those who plan, provide or receive care in the NHS. HTA research is undertaken where some evidence already exists to show that a technology can be effective and this needs to be compared to the current standard NHS intervention to see which works best. The term health technology can cover any intervention used in the treatment, prevention or diagnosis of disease. This could mean research evaluating for example, devices, procedures, drugs, settings of care or screening, provided the study outcomes lead to findings that have the potential to be of direct benefit to NHS patients.the HTA Programme has two main work streams: researcherled and commissioned. The researcher-led work stream, Clinical Evaluation and Trials (CET), offers researchers the opportunity to submit proposals on topics or research questions within the programme s remit. There are three cut-off dates a year when applications will be considered. YES. This funding stream is relevant to newborn screening. 9 The commissioned work stream invites applications in

10 EME Efficacy and Mechanisms Evaluation (EME) response to calls for research on specific questions which have been identified and prioritised for their importance to the NHS and patients. Proposals may include primary research, evidence synthesis, or feasibility and pilot studies. The programme supports clinical trials and evaluative studies in patients which evaluate clinical efficacy of interventions where proof of concept in humans has already been achieved, add significantly to our understanding of biological or behavioural mechanisms and processes, or explore new scientific or clinical principles; and include the development or testing of new methodologies. This can be used to fund research on new diagnostic tests or new treatments for a disorder. It is generally for the research stage before the HTA. There are two work streams, researcher-led and commissioned. Both work streams fund large projects with clear stages and milestones. Proposals may include pilot and feasibility studies and late development of technologies. The programme welcomes collaborations with industry and charities. RfPB Research for Patient Benefit (RfPB) The Research for Patient Benefit Programme (RfPB) funds NHS research covering a wide range of health service challenges. The aim of the programme is to fund topics and research methodologies that increase the effectiveness of NHS services, provide value for money and benefit patients. Research topics for funding are researcher-led. YES. This funding source is relevant to newborn screening and it has been used in the past. The projects funded are for regionally-derived applied research in health services and social care. The programme s strong regional element is unique within the NIHR s research programmes. 10

11 Applicants need to demonstrate the regional benefits of the proposed research, although studies with national benefit will also be considered. Members of the regional panels, including members of the public and service users, that assess the applications are drawn from local academic institutions and health organisations. All researchers in the NHS in England can apply, and joint applications with academic partners are encouraged. RfPB funds up to 350,000 per project for up to 36 months in duration. The programme supports: studies of the provision and use of NHS services evaluations of the effectiveness and cost effectiveness of interventions examination of the resource utilisation of alternative means for healthcare delivery scrutinising innovations and developments feasibility studies to help reach the next step of a definitive trial. CLHARC Collaboration for Leadership in Applied Health Research and Care (CLHARC) Collaborations for Leadership in Applied Health Research and Care (CLAHRCs) are funded by the National Institute for Health Research and undertake high-quality applied health research focused on the needs of patients and support the translation of research evidence into YES. This funding source is relevant to newborn screening and has been used in the past. 11

12 practice in the NHS. PGfAR Programme Grants for Applied Research (PGfAR) CLAHRCs are collaborative partnerships between a university and the surrounding NHS organisations, focused on improving patient outcomes through the conduct and application of applied health research. They create and embed approaches to research and its dissemination that are specifically designed to take account of the way that health care is increasingly delivered across sectors and a wide geographical area. There are currently 13 CLHARC's in the UK. Programme Grants for Applied Research (PGfAR) fund research studies requiring a multidisciplinary approach that will have practical application for the benefit of patients and the NHS, typically through improved healthcare or better healthcare delivery in the relatively near future (within three to five years of a programme s end). Topics for funding are researcher-led and particular emphasis is given to conditions causing significant disease burden. The programmes funded are interrelated research projects requiring input from, for example, clinical, health economics, statistics, qualitative and behavioural sciences backgrounds to ensure that research objectives can be met. This is as relevant as RfPB. If a number of pieces of screening evidence need generating around a single condition, the PGfAR would be a good vehicle. This is providing we can achieve the answers to our research questions within the 2+ million limit. The programme supports applied health research (including health services research), public health research, behavioural research, economic evaluations and 12

13 modelling. Applicants should be balanced teams of leading researchers from the NHS and academia working together, who can demonstrate an impressive track record of achievement in applied health research. SR Programme Systematic Reviews (SR) Programme The amount awarded and the length of the funding period depends on the nature of the proposed work, in particular whether or not the proposal includes a substantial powered trial, although funding in excess of 2.5m over more than six years will be unusual. The Systematic Reviews Programme consists of a number of initiatives including the Cochrane Review Groups, the UK Cochrane Centre and the Health Technology Assessment Reviews, which provide high-quality research evidence to support decision-making. Systematic reviews identify, evaluate, combine and summarise the findings of all relevant individual studies, to provide decision makers with the best possible information about the effects of tests, treatments and other interventions used in health and social care. This funding stream is relevant to newborn screening. There will be questions around a treatment, test or disease prevalence that may be answered by a systematic review. The SR Programme supports the production and updates of systematic reviews both by core infrastructure funding and open competition via two funding streams: the Cochrane Collaborations Programme Grant Scheme and the Cochrane Incentive Awards. The Cochrane Collaborations Programme Grant Scheme supports high quality systematic reviews that are of direct benefit to users of the NHS in England. This call runs every 13

14 three years. The Cochrane Incentive Awards are available to Cochrane Review Groups to facilitate, and possibly accelerate, activity that is already planned or is underway. This call runs annually. PHR Programme Public Health Research Programme The PHR Programme funds research that evaluates public health interventions, providing new knowledge on the benefits, costs, acceptability and wider impacts of non-nhs interventions intended to improve the health of the public and reduce inequalities in health. The scope of the PHR Programme is multidisciplinary and broad, covering a range of public health interventions. Examples include examining whether regeneration programmes improve public health and reduce health inequalities, evaluating employer schemes to encourage walking or cycling to work and assessing interventions that encourage healthy eating among school children. This funding stream has been included for completeness however we are not certain if it is relevant to newborn screening research or pilot studies. Even though screening is a public health activity, the presence or absence of the condition we are looking to consider may not have a wide public health impact in the same way as e.g. cancer screening programmes. 14

NIHR funding programmes. Twitter: NIHR YouTube: NIHRtv

NIHR funding programmes.  Twitter: NIHR YouTube: NIHRtv NIHR funding programmes www.nihr.ac.uk Twitter: NIHR Research @OfficialNIHR YouTube: NIHRtv NIHR funded research programmes on the Research Pathway Invention Evaluation Adoption Efficacy and Mechanism

More information

Funding opportunities

Funding opportunities Funding opportunities for research and for career development funding leading-edge research and supporting research professionals Contents Introduction 1 Research programmes Efficacy and Mechanism Evaluation

More information

NIHR Funding For further assistance with NIHR funding please contact the Protocol Development Service

NIHR Funding For further assistance with NIHR funding please contact the Protocol Development Service Programme Grants for Applied Research http://www.nihr-ccf.org.uk/site/programmes/programmes/default.cfm Prestigious awards of up to 2m over a period of three to five years to fund a series of related projects,

More information

Applying for NIHR Funding

Applying for NIHR Funding Applying for NIHR Funding Dr Jenny Ingram Joanne Simon Research Design Service South West Bristol Randomised Trials Collaboration, University of Bristol Applying for NIHR funding Introduction to NIHR funding

More information

~ RESEARCH FUNDING UPDATE ~ Projects & Programmes 18 th November 2013

~ RESEARCH FUNDING UPDATE ~ Projects & Programmes 18 th November 2013 Page 1 of 10 30 B 5CC0000 www.rds-yh.nihr.ac.uk The NIHR Research Design Service for Yorkshire and Humber ~ RESEARCH FUNDING UPDATE ~ Projects & Programmes 18 th November 2013 Join our email alert list

More information

Eligibility Criteria for NIHR Clinical Research Network Support

Eligibility Criteria for NIHR Clinical Research Network Support Eligibility Criteria for NIHR Clinical Research Network Support December 2017 Title: Eligibility Criteria for NIHR Clinical Research Network Support Author: Authored by NIHR Clinical Research Network.

More information

NIHR Funding Opportunities

NIHR Funding Opportunities NIHR Funding Opportunities David King Newcastle 12 th May, 2008 Consultation 2005 New Government Strategy 2006 Best for Best Health Vision To create a health research system in which the NHS: supports

More information

By to:

By  to: From the Director of Research and Development Dr Russell Hamilton CBE Richmond House 79 Whitehall London SW1A 2NS T: +44 (0)20 7210 5828 E: russell.hamilton@dh.gsi.gov.uk W: www.gov.uk 18 December 2015

More information

NETSCC Needs-led and science-added management of evaluation research on behalf of the National Institute for Health Research

NETSCC Needs-led and science-added management of evaluation research on behalf of the National Institute for Health Research NETSCC Needs-led and science-added management of evaluation research on behalf of the National Institute for Health Research The NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC) manages

More information

RESPONSE TO RECOMMENDATIONS FROM THE HEALTH & SOCIAL CARE COMMITTEE: INQUIRY INTO ACCESS TO MEDICAL TECHNOLOGIES IN WALES

RESPONSE TO RECOMMENDATIONS FROM THE HEALTH & SOCIAL CARE COMMITTEE: INQUIRY INTO ACCESS TO MEDICAL TECHNOLOGIES IN WALES Recommendations 1, 2, 3 1. That the Minister for Health and Social Services should, as a matter of priority, identify means by which a more strategic, coordinated and streamlined approach to medical technology

More information

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Interim Process and Methods of the Highly Specialised Technologies Programme

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Interim Process and Methods of the Highly Specialised Technologies Programme NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Principles Interim Process and Methods of the Highly Specialised Technologies Programme 1. Our guidance production processes are based on key principles,

More information

Overview of NIHR structure, and funding streams. Prof James Mason, Co-Director, RDS NE

Overview of NIHR structure, and funding streams. Prof James Mason, Co-Director, RDS NE Overview of NIHR structure, and funding streams Prof James Mason, Co-Director, RDS NE The National Institute for Health Research (NIHR) DH-funded, est. April 2006 Increasing applied health research and

More information

Research topic identification & the funding process

Research topic identification & the funding process Research topic identification & the funding process Gemma Bashevoy Research Fellow, Topic Identification Team NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC) 3/11/2017 Overview National

More information

NETSCC. Needs-led and science-added management of evaluation research on behalf of the National Institute of Health Research

NETSCC. Needs-led and science-added management of evaluation research on behalf of the National Institute of Health Research NIHR Evaluation, Trials and Studies Coordinating Centre NETSCC funding for evaluation research in health Needs-led and science-added management of evaluation research on behalf of the National Institute

More information

1. The Department funds R&D through two main routes:

1. The Department funds R&D through two main routes: House of Lords Science and Technology Committee Call for Evidence: Setting science and technology research funding priorities Submission from the Department of Health Introduction 1. The Department funds

More information

abcdefghijklmnopqrstu

abcdefghijklmnopqrstu Healthcare Policy and Strategy Directorate Quality Division Dear Colleague INTRODUCTION AND AVAILABILITY OF NEWLY LICENSED MEDICINES IN THE NHS IN SCOTLAND Dear Colleague This guidance sets out the policy

More information

Prostate Cancer UK 2014 Call for Movember Translational Research Grants - Guidance Notes

Prostate Cancer UK 2014 Call for Movember Translational Research Grants - Guidance Notes Prostate Cancer UK 2014 Call for Movember Translational Research Grants - Guidance Notes Remit Through this call we aim to fund research that takes early stage basic discoveries that we and/or others have

More information

White Paper consultation Healthy lives, healthy people: Our strategy for public health in England

White Paper consultation Healthy lives, healthy people: Our strategy for public health in England White Paper consultation Healthy lives, healthy people: Our strategy for public health in England Response submitted by the British Nutrition Foundation March 2011 The British Nutrition Foundation (BNF)

More information

Methods: Commissioning through Evaluation

Methods: Commissioning through Evaluation Methods: Commissioning through Evaluation NHS England INFORMATION READER BOX Directorate Medical Operations and Information Specialised Commissioning Nursing Trans. & Corp. Ops. Commissioning Strategy

More information

DRAFT - NHS CHC and Complex Care Commissioning Policy.

DRAFT - NHS CHC and Complex Care Commissioning Policy. DRAFT - NHS CHC and Complex Care Commissioning Policy. 1. Introduction 1.1 This policy describes the way the following Clinical Commissioning Groups (CCGs) NHS Wirral Clinical Commissioning Group, NHS

More information

Newborn bloodspot screening

Newborn bloodspot screening Policy HUMAN GENETICS SOCIETY OF AUSTRALASIA ARBN. 076 130 937 (Incorporated Under the Associations Incorporation Act) The liability of members is limited RACP, 145 Macquarie Street, Sydney NSW 2000, Australia

More information

Health Services and Delivery Research Programme

Health Services and Delivery Research Programme Health Services and Delivery Research Programme NIHR Health Services and Delivery Research (HS&DR) programme Researcher-led workstream (Standard Stage 1 to Stage 2): Specification Closing date: 1pm, 06

More information

Physiotherapy Research Foundation (PRF): research project grants Chartered Society of Physiotherapy (CSP) Charitable Trust registered charity

Physiotherapy Research Foundation (PRF): research project grants Chartered Society of Physiotherapy (CSP) Charitable Trust registered charity Physiotherapy Research Foundation (PRF): research project grants Chartered Society of Physiotherapy (CSP) Charitable Trust registered charity 279882 Guidance notes for PRF (Schemes A&B) OUTLINE applications

More information

Standards of Proficiency for Higher Specialist Scientists

Standards of Proficiency for Higher Specialist Scientists Standards of Proficiency for Higher Specialist Scientists July 2015 Version 1.0 Review date: 31 July 2016 Contents Introduction... 3 About the Academy Register - Practitioner part... 3 Routes to registration...

More information

Safer Care Conference: 26 th June 2014: 1515 session Accessing funding: THE WEST MIDLANDS RESEARCH DESIGN SERVICE

Safer Care Conference: 26 th June 2014: 1515 session Accessing funding: THE WEST MIDLANDS RESEARCH DESIGN SERVICE Safer Care Conference: 26 th June 2014: 1515 session Accessing funding: THE WEST MIDLANDS RESEARCH DESIGN SERVICE Dr George Dowswell Deputy Director: Birmingham Hub of WMRDS PLAN FOR SESSION Background

More information

21 March NHS Providers ON THE DAY BRIEFING Page 1

21 March NHS Providers ON THE DAY BRIEFING Page 1 21 March 2018 NHS Providers ON THE DAY BRIEFING Page 1 2016-17 (Revised) 2017-18 (Revised) 2018-19 2019-20 (Indicative budget) 2020-21 (Indicative budget) Total revenue budget ( m) 106,528 110,002 114,269

More information

WELLBEING OF WOMEN RESEARCH PROJECT GRANTS 2018 GUIDELINES FOR APPLICANTS

WELLBEING OF WOMEN RESEARCH PROJECT GRANTS 2018 GUIDELINES FOR APPLICANTS WELLBEING OF WOMEN RESEARCH GRANT APPLICANT GUIDELINES 2018 Amended October 2017 WELLBEING OF WOMEN RESEARCH PROJECT GRANTS 2018 GUIDELINES FOR APPLICANTS TABLE OF CONTENTS About Wellbeing of Women...

More information

Response to the Department for Education Consultation on the Draft Degree Apprenticeship Registered Nurse September 2016 Background

Response to the Department for Education Consultation on the Draft Degree Apprenticeship Registered Nurse September 2016 Background Response to the Department for Education Consultation on the Draft Degree Apprenticeship Registered Nurse September 2016 Background This document sets out our response to the Department for Education s

More information

NHS. The guideline development process: an overview for stakeholders, the public and the NHS. National Institute for Health and Clinical Excellence

NHS. The guideline development process: an overview for stakeholders, the public and the NHS. National Institute for Health and Clinical Excellence NHS National Institute for Health and Clinical Excellence Issue date: April 2007 The guideline development process: an overview for stakeholders, the public and the NHS Third edition The guideline development

More information

GUIDANCE ON SUPPORTING INFORMATION FOR REVALIDATION FOR SURGERY

GUIDANCE ON SUPPORTING INFORMATION FOR REVALIDATION FOR SURGERY ON SUPPORTING INFORMATION FOR REVALIDATION FOR SURGERY Based on the Academy of Medical Royal Colleges and Faculties Core Guidance for all doctors GENERAL INTRODUCTION JUNE 2012 The purpose of revalidation

More information

Mental Health Act Approval of Approved Clinicians in Wales

Mental Health Act Approval of Approved Clinicians in Wales Mental Health Act 1983 Approval of Approved Clinicians in Wales March 2011 Crown copyright 2011 ISBN 978 0 7504 6058 3 WAG 10-11545 F7311011 Approval of Approved Clinicians in Wales Introduction...2 Who

More information

BBRSC, MRC and Wellcome Trust response to the Bateson Review Recommendations. July 2011

BBRSC, MRC and Wellcome Trust response to the Bateson Review Recommendations. July 2011 BBRSC, MRC and Wellcome Trust response to the Bateson Review Recommendations July 2011 Recommendation 1: The Panel noted that the processes needed to maximise scientific quality and impact are already

More information

Are you responding as an individual or on behalf of an organisation?

Are you responding as an individual or on behalf of an organisation? Response form Address: 407 St John Street, London, EC1V 4AD Are you responding as an individual or on behalf of an organisation? If as an individual, are you responding as: a) a doctor? b) a patient? c)

More information

European network of paediatric research (EnprEMA)

European network of paediatric research (EnprEMA) 17 February 2012 EMA/77450/2012 Human Medicines Development and Evaluation Recognition criteria for self assessment The European Medicines Agency is tasked with developing a European paediatric network

More information

NICE Charter Who we are and what we do

NICE Charter Who we are and what we do NICE Charter 2017 Who we are and what we do 1. The National Institute for Health and Care Excellence (NICE) is the independent organisation responsible for providing evidence-based guidance on health and

More information

Process and methods Published: 23 January 2017 nice.org.uk/process/pmg31

Process and methods Published: 23 January 2017 nice.org.uk/process/pmg31 Evidence summaries: process guide Process and methods Published: 23 January 2017 nice.org.uk/process/pmg31 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).

More information

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Centre for Health Technology Evaluation

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Centre for Health Technology Evaluation NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Centre for Health Technology Evaluation Increasing capacity within Technology Appraisals Consultation comments proforma Name Role Organisation E-Mail Address

More information

Stroke in Young Adults Funding Opportunity for Mid- Career Researchers. Guidelines for Applicants

Stroke in Young Adults Funding Opportunity for Mid- Career Researchers. Guidelines for Applicants Stroke in Young Adults Funding Opportunity for Mid- Career Researchers Guidelines for Applicants 1 Summary This document guides you through the preparation and submission of an application for the Stroke

More information

The British Society of Haematology and NIHR Clinical Research Network Award scheme to recognise NHS consultants and trainees active in research

The British Society of Haematology and NIHR Clinical Research Network Award scheme to recognise NHS consultants and trainees active in research The British Society of Haematology and NIHR Clinical Research Network Award scheme to recognise NHS consultants and trainees active in research Please send completed applications to ian.nickson@nihr.ac.uk

More information

REFLECTION PROCESS on CHRONIC DISEASES INTERIM REPORT

REFLECTION PROCESS on CHRONIC DISEASES INTERIM REPORT REFLECTION PROCESS on CHRONIC DISEASES INTERIM REPORT A. INTRODUCTION REFLECTION PROCESS In conclusions adopted in March 2010, the Council called upon the Commission and Member States to launch a reflection

More information

COMMISSIONING SUPPORT PROGRAMME. Standard operating procedure

COMMISSIONING SUPPORT PROGRAMME. Standard operating procedure NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE COMMISSIONING SUPPORT PROGRAMME Standard operating procedure April 2018 1. Introduction The Commissioning Support Programme (CSP) at NICE supports the

More information

NIHR COCHRANE COLLABORATION PROGRAMME GRANT SCHEME

NIHR COCHRANE COLLABORATION PROGRAMME GRANT SCHEME NIHR COCHRANE COLLABORATION PROGRAMME GRANT SCHEME GUIDELINES FOR APPLICANTS The NIHR Cochrane Collaboration Programme Grant Scheme was established to provide high quality systematic reviews that will

More information

National Institute for Health and Clinical Excellence. The guidelines manual

National Institute for Health and Clinical Excellence. The guidelines manual National Institute for Health and Clinical Excellence The guidelines manual January 2009 The guidelines manual About this document This document describes the methods used in the development of NICE guidelines.

More information

Process and methods Published: 30 November 2012 nice.org.uk/process/pmg6

Process and methods Published: 30 November 2012 nice.org.uk/process/pmg6 The guidelines manual Process and methods Published: 30 November 2012 nice.org.uk/process/pmg6 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).

More information

Supporting information for appraisal and revalidation: guidance for psychiatry

Supporting information for appraisal and revalidation: guidance for psychiatry Supporting information for appraisal and revalidation: guidance for psychiatry Based on the Academy of Medical Royal Colleges and Faculties Core for all doctors. General Introduction The purpose of revalidation

More information

Guidance on supporting information for revalidation

Guidance on supporting information for revalidation Guidance on supporting information for revalidation Including specialty-specific information for medical examiners (of the cause of death) General introduction The purpose of revalidation is to assure

More information

NEW FRAMEWORK FOR SCIENTIFIC ADVICE & PROTOCOL ASSISTANCE

NEW FRAMEWORK FOR SCIENTIFIC ADVICE & PROTOCOL ASSISTANCE European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use EMEA/267187/2005/ Rev. 1 London, 26 April 2006 NEW FRAMEWORK FOR SCIENTIFIC ADVICE & PROTOCOL ASSISTANCE The CPMP/CHMP

More information

Draft National Quality Assurance Criteria for Clinical Guidelines

Draft National Quality Assurance Criteria for Clinical Guidelines Draft National Quality Assurance Criteria for Clinical Guidelines Consultation document July 2011 1 About the The is the independent Authority established to drive continuous improvement in Ireland s health

More information

European Reference Networks. Guidance on the recognition of Healthcare Providers and UK Oversight of Applications

European Reference Networks. Guidance on the recognition of Healthcare Providers and UK Oversight of Applications European Reference Networks Guidance on the recognition of Healthcare Providers and UK Oversight of Applications NHS England INFORMATION READER BOX Directorate Medical Commissioning Operations Patients

More information

Mental Health (Wales) Measure Implementing the Mental Health (Wales) Measure Guidance for Local Health Boards and Local Authorities

Mental Health (Wales) Measure Implementing the Mental Health (Wales) Measure Guidance for Local Health Boards and Local Authorities Mental Health (Wales) Measure 2010 Implementing the Mental Health (Wales) Measure 2010 Guidance for Local Health Boards and Local Authorities Januar y 2011 Crown copyright 2011 WAG 10-11316 F6651011 Implementing

More information

Supporting information for appraisal and revalidation: guidance for pharmaceutical medicine

Supporting information for appraisal and revalidation: guidance for pharmaceutical medicine Supporting information for appraisal and revalidation: guidance for pharmaceutical medicine Based on the Academy of Medical Royal Colleges and Faculties Core for all doctors. General Introduction The purpose

More information

Standards conduct, accountability

Standards conduct, accountability Standards of conduct, accountability and openness Standards of conduct, accountability and openness Throughout this document: members refers to all members of a board the Chair, the non-executives, the

More information

This is the consultation responses analysis put together by the Hearing Aid Council and considered at their Council meeting on 12 November 2008

This is the consultation responses analysis put together by the Hearing Aid Council and considered at their Council meeting on 12 November 2008 Analysis of responses - Hearing Aid Council and Health Professions Council consultation on standards of proficiency and the threshold level of qualification for entry to the Hearing Aid Audiologists/Dispensers

More information

CCG Policy for Working with the Pharmaceutical Industry

CCG Policy for Working with the Pharmaceutical Industry CCG Policy for Working with the Pharmaceutical Industry 1. Introduction Medicines are the most frequently and widely used NHS treatment and account for over 12% of NHS expenditure. The Pharmaceutical Industry

More information

Health Technology Assessment (HTA) Good Practices & Principles FIFARMA, I. Government s cost containment measures: current status & issues

Health Technology Assessment (HTA) Good Practices & Principles FIFARMA, I. Government s cost containment measures: current status & issues KeyPointsforDecisionMakers HealthTechnologyAssessment(HTA) refers to the scientific multidisciplinary field that addresses inatransparentandsystematicway theclinical,economic,organizational, social,legal,andethicalimpactsofa

More information

Supporting information for appraisal and revalidation: guidance for Occupational Medicine, June 2014

Supporting information for appraisal and revalidation: guidance for Occupational Medicine, June 2014 Supporting information for appraisal and revalidation: guidance for Occupational Medicine, June 2014 Based on the Academy of Medical Royal Colleges and Faculties Core for all doctors. General Introduction

More information

Supporting information for appraisal and revalidation: guidance for Occupational Medicine, April 2013

Supporting information for appraisal and revalidation: guidance for Occupational Medicine, April 2013 Supporting information for appraisal and revalidation: guidance for Occupational Medicine, April 2013 Based on the Academy of Medical Royal Colleges and Faculties Core for all doctors. General Introduction

More information

Developing. National Service Frameworks

Developing. National Service Frameworks Developing National Service Frameworks A guide for policy colleagues developing National Service Frameworks for Healthcare services in Wales 1 Background 1. National Service Frameworks (NSF) were originally

More information

Ethical framework for priority setting and resource allocation

Ethical framework for priority setting and resource allocation Ethical framework for priority setting and resource allocation UNIQUE REF NUMBER: CD/XX/083/V2.0 DOCUMENT STATUS: Approved - Commissioning Development Committee 16 August 2017 DATE ISSUED: August 2017

More information

The Yorkshire & Humber Improvement Academy Clinical Leadership Training Programme

The Yorkshire & Humber Improvement Academy Clinical Leadership Training Programme The Yorkshire & Humber Improvement Academy Clinical Leadership Training Programme The Improvement Academy (IA) is one of the leading quality and safety improvement networks in the UK. The IA works across

More information

INTRODUCTION TO THE UK PUBLIC HEALTH REGISTER ROUTE TO REGISTRATION FOR PUBLIC HEALTH PRACTITIONERS

INTRODUCTION TO THE UK PUBLIC HEALTH REGISTER ROUTE TO REGISTRATION FOR PUBLIC HEALTH PRACTITIONERS INTRODUCTION TO THE UK PUBLIC HEALTH REGISTER ROUTE TO REGISTRATION FOR PUBLIC HEALTH PRACTITIONERS This introduction consists of: 1. Introduction to the UK Public Health Register 2. Process and Structures

More information

High Level Pharmaceutical Forum

High Level Pharmaceutical Forum High Level Pharmaceutical Forum 2005-2008 Final Conclusions and Recommendations of the High Level Pharmaceutical Forum On 2 nd October 2008, the High Level Pharmaceutical Forum agreed on the following

More information

Tissue Viability Society. Strategy A future plan for the Tissue Viability Society (TVS) where we are going and how we will get there...

Tissue Viability Society. Strategy A future plan for the Tissue Viability Society (TVS) where we are going and how we will get there... Tissue Viability Society Tissue Viability Society Strategy 2017 2019 A future plan for the Tissue Viability Society (TVS) where we are going and how we will get there... 1 CONTENTS OBJECTIVES 2 MISSION

More information

Supporting information for appraisal and revalidation: guidance for Supporting information for appraisal and revalidation: guidance for ophthalmology

Supporting information for appraisal and revalidation: guidance for Supporting information for appraisal and revalidation: guidance for ophthalmology FOREWORD As part of revalidation, doctors will need to collect and bring to their appraisal six types of supporting information to show how they are keeping up to date and fit to practise. The GMC has

More information

NHS Governance Clinical Governance General Medical Council

NHS Governance Clinical Governance General Medical Council NHS Governance Clinical Governance General Medical Council Thank you for the opportunity to respond to this call for evidence. The GMC has a particular role in clinical governance, as outlined below, and

More information

6 TH CALL FOR PROPOSALS: FREQUENTLY ASKED QUESTIONS

6 TH CALL FOR PROPOSALS: FREQUENTLY ASKED QUESTIONS 6 TH CALL FOR PROPOSALS: FREQUENTLY ASKED QUESTIONS MARCH 2018 Below are some of the most common questions asked concerning the R2HC Calls for Proposals. Please check this list of questions before contacting

More information

Clinical Practice Guideline Development Manual

Clinical Practice Guideline Development Manual Clinical Practice Guideline Development Manual Publication Date: September 2016 Review Date: September 2021 Table of Contents 1. Background... 3 2. NICE accreditation... 3 3. Patient Involvement... 3 4.

More information

Financial mechanisms for integrating funds across health & social care

Financial mechanisms for integrating funds across health & social care Financial mechanisms for integrating funds across health & social care Do they enable integrated care? Anne Mason, Maria Goddard, Helen Weatherly 4th International Conference on Integrated Care Brussels

More information

Centre for Cultural Value

Centre for Cultural Value Centre for Cultural Value Call Specification Contents 1. Summary.2 2. Background 2 3. Eligibility: who can apply?..3 4. Scope.3 5. Functions of the Centre for Cultural Value.4 6. Design of the Centre 4

More information

Visitors report. Contents. Doctorate in Health Psychology (Dpsych) Full time Part time. Programme name. Mode of delivery. Date of visit 7 8 June 2012

Visitors report. Contents. Doctorate in Health Psychology (Dpsych) Full time Part time. Programme name. Mode of delivery. Date of visit 7 8 June 2012 Visitors report Name of education provider Programme name Mode of delivery Relevant part of HPC Register Relevant modality / domain City University Doctorate in Health Psychology (Dpsych) Full time Part

More information

Delivering Local Health Care

Delivering Local Health Care Delivering Local Health Care Accelerating the pace of change Contents Joint foreword by the Minister for Health and Social Services and the Deputy Minister for Children and Social Services Foreword by

More information

Appendix 1 MORTALITY GOVERNANCE POLICY

Appendix 1 MORTALITY GOVERNANCE POLICY Appendix 1 MORTALITY GOVERNANCE POLICY 1 Policy Title: Executive Summary: Mortality Governance Policy For many people death under the care of the NHS is an inevitable outcome and they experience excellent

More information

UKMi and Medicines Optimisation in England A Consultation

UKMi and Medicines Optimisation in England A Consultation UKMi and Medicines Optimisation in England A Consultation Executive Summary Medicines optimisation is an approach that seeks to maximise the beneficial clinical outcomes for patients from medicines with

More information

European Haemophilia Consortium

European Haemophilia Consortium European Haemophilia Consortium Response to the European Commission Public Consultation on rare diseases: Europe s challenges The European Haemophilia Consortium 1 (EHC) is a European patient group representing

More information

SCHOOL OF NURSING DEVELOP YOUR NURSING CAREER WITH THE UNIVERSITY OF BIRMINGHAM

SCHOOL OF NURSING DEVELOP YOUR NURSING CAREER WITH THE UNIVERSITY OF BIRMINGHAM SCHOOL OF NURSING DEVELOP YOUR NURSING CAREER WITH THE UNIVERSITY OF BIRMINGHAM 2 English Language and Applied Linguistics Welcome to Nursing at the University of Birmingham We continuously develop our

More information

English devolution deals

English devolution deals Report by the Comptroller and Auditor General Department for Communities and Local Government and HM Treasury English devolution deals HC 948 SESSION 2015-16 20 APRIL 2016 4 Key facts English devolution

More information

During the one session on value based assessment (VBA), the audience heard from 3 speakers:

During the one session on value based assessment (VBA), the audience heard from 3 speakers: The chair of NICE, David Haslam, initiated the conference by focussing on the importance of NICE and other health technology assessment (HTA) bodies in terms of the need for technology appraisal in a world

More information

Efficiency Research Programme

Efficiency Research Programme Efficiency Research Programme A Health Foundation call for innovative research on system efficiency and sustainability in health and social care Frequently asked questions April 2016 Table of contents

More information

The Newcastle upon Tyne Hospitals NHS Foundation Trust. Implementation Policy for NICE Guidelines

The Newcastle upon Tyne Hospitals NHS Foundation Trust. Implementation Policy for NICE Guidelines The Newcastle upon Tyne Hospitals NHS Foundation Trust Implementation Policy for NICE Guidelines Version No.: 5.3 Effective From: 08 May 2017 Expiry Date: 02 March 2019 Date Ratified: 23 February 2017

More information

Introduction Patient-Centered Outcomes Research Institute (PCORI)

Introduction Patient-Centered Outcomes Research Institute (PCORI) 2 Introduction The Patient-Centered Outcomes Research Institute (PCORI) is an independent, nonprofit health research organization authorized by the Patient Protection and Affordable Care Act of 2010. Its

More information

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Health and Social Care Directorate Quality standards Process guide

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Health and Social Care Directorate Quality standards Process guide NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Health and Social Care Directorate Quality standards Process guide December 2014 Quality standards process guide Page 1 of 44 About this guide This guide

More information

Guide to the Continuing NHS Healthcare Assessment Process

Guide to the Continuing NHS Healthcare Assessment Process Guide to the Continuing NHS Healthcare Assessment Process Continuing NHS Healthcare (CHC) is a package of care arranged and funded solely by the NHS, where it has been assessed that the person s primary

More information

Learning from Deaths Policy

Learning from Deaths Policy Learning from Deaths Policy Version: 3 Approved by: Board of Directors Date Approved: October 2017 Lead Manager: Associate Medical Director for Patient Safety and Clinical Risk Responsible Director: Medical

More information

NIHR BIOMEDICAL RESEARCH CENTRES FREQUENTLY ASKED QUESTIONS

NIHR BIOMEDICAL RESEARCH CENTRES FREQUENTLY ASKED QUESTIONS NIHR BIOMEDICAL RESEARCH CENTRES FREQUENTLY ASKED QUESTIONS This note provides the answers to Frequently Asked Questions relating to the NIHR Biomedical Research Centre (BRC) funding scheme, and is intended

More information

Policy reference Policy product type LGiU essential policy briefing Published date 08/12/2010. This covers England.

Policy reference Policy product type LGiU essential policy briefing Published date 08/12/2010. This covers England. 1 of 7 23/03/2012 15:23 Healthy Lives, Healthy People: Public Health White Paper Policy reference 201000810 Policy product type LGiU essential policy briefing Published date 08/12/2010 Author Janet Sillett

More information

JOB DESCRIPTION DIRECTOR OF SCREENING. Author: Dr Quentin Sandifer, Executive Director of Public Health Services and Medical Director

JOB DESCRIPTION DIRECTOR OF SCREENING. Author: Dr Quentin Sandifer, Executive Director of Public Health Services and Medical Director JOB DESCRIPTION DIRECTOR OF SCREENING Author: Dr Quentin Sandifer, Executive Director of Public Health Services and Medical Director Date: 1 November 2017 Version: 0d Purpose and Summary of Document: This

More information

Cancer Research UK response to the Business, Innovation and Skills Committee inquiry into the Government s industrial strategy September 2016

Cancer Research UK response to the Business, Innovation and Skills Committee inquiry into the Government s industrial strategy September 2016 Cancer Research UK response to the Business, Innovation and Skills Committee inquiry into the Government s industrial strategy September 2016 Cancer Research UK is the world s largest independent cancer

More information

EUCERD RECOMMENDATIONS QUALITY CRITERIA FOR CENTRES OF EXPERTISE FOR RARE DISEASES IN MEMBER STATES

EUCERD RECOMMENDATIONS QUALITY CRITERIA FOR CENTRES OF EXPERTISE FOR RARE DISEASES IN MEMBER STATES EUCERD RECOMMENDATIONS QUALITY CRITERIA FOR CENTRES OF EXPERTISE FOR RARE DISEASES IN MEMBER STATES 24 OCTOBER 2011 INTRODUCTION 1. THE EUROPEAN CONTEXT Centres of expertise (CE) and European Reference

More information

MRC Funding and Translational Research. Dr Catriona Crombie

MRC Funding and Translational Research. Dr Catriona Crombie MRC Funding and Translational Research Dr Catriona Crombie Medical Research Council The Medical Research Council is dedicated to improving human health through the best scientific research. Its work, on

More information

Imperial College Health Partners - at a glance

Imperial College Health Partners - at a glance Imperial College Health Partners - at a glance Imperial College Health Partners - at a glance Our vision and purpose This document is intended to provide an introduction to Imperial College Health Partners

More information

CORRESPONDING AUTHOR:

CORRESPONDING AUTHOR: TITLE: A paediatrician s guide to Clinical Trials Units AUTHORS: Chris Gale, Edmund Juszczak CORRESPONDING AUTHOR: Dr C Gale, NIHR Clinical Trials Fellow, Imperial Clinical Trials Unit and section of Neonatal

More information

Strategic Plan

Strategic Plan Strategic Plan 2018-2021. 1 1. Introduction The British Gas Energy Trust (BGET), which incorporates the Scottish Gas Energy Trust, is an independent Charitable Trust established in 2004 and funded solely

More information

Response to NHS England s consultation on Supporting research in the NHS on excess treatment costs and clinical research set-up January 2018

Response to NHS England s consultation on Supporting research in the NHS on excess treatment costs and clinical research set-up January 2018 Response to NHS England s consultation on Supporting research in the NHS on excess treatment costs and clinical research set-up January 2018 Summary The Academy welcomes NHS England s proposals to better

More information

Data, analysis and evidence

Data, analysis and evidence 1 New Congenital Heart Disease Review Data, analysis and evidence Joanna Glenwright 2 New Congenital Heart Disease Review Evidence for standards Joanna Glenwright Evidence to inform the service standards

More information

SCIENCE COMMITTEE PROGRAMME FOUNDATION AWARDS OUTLINE APPLICATION GUIDELINES

SCIENCE COMMITTEE PROGRAMME FOUNDATION AWARDS OUTLINE APPLICATION GUIDELINES SCIENCE COMMITTEE PROGRAMME FOUNDATION AWARDS OUTLINE APPLICATION GUIDELINES CONTENTS i. CHECKLIST... 2 1. INTRODUCTION... 3 1.1. Purpose of the guidelines... 3 1.2. About CRUK... 3 1.3. About the award...

More information

Vanguard Programme: Acute Care Collaboration Value Proposition

Vanguard Programme: Acute Care Collaboration Value Proposition Vanguard Programme: Acute Care Collaboration Value Proposition 2015-16 November 2015 Version: 1 30 November 2015 ACC Vanguard: Moorfields Eye Hospital Value Proposition 1 Contents Section Page Section

More information

Guidance Notes NIHR Fellowships, Round 11 October 2017

Guidance Notes NIHR Fellowships, Round 11 October 2017 Guidance Notes NIHR Fellowships, Round 11 October 2017 Trainees Coordinating Centre Contents Introduction... 3 NIHR Doctoral Research Fellowship... 4 NIHR Post Doctoral Fellowship... 5 NIHR Transitional

More information

INVEST NI INNOVATION VOUCHER SAMPLE ON-LINE APPLICATION FORM SAMPLE APPLICATION. Applications must be submitted through our online application form.

INVEST NI INNOVATION VOUCHER SAMPLE ON-LINE APPLICATION FORM SAMPLE APPLICATION. Applications must be submitted through our online application form. INVEST NI INNOVATION VOUCHER SAMPLE ON-LINE APPLICATION FORM SAMPLE APPLICATION This is a sample application to assist applicants in preparing their application prior to submitting an online application

More information

Ordinary Residence and Continuity of Care Policy

Ordinary Residence and Continuity of Care Policy COMMUNITY WELLBEING AND SOCIAL CARE DIRECTORATE Director of Adult Social Services Isle of Wight Council Adult Social Care Ordinary Residence and Continuity of Care Policy August 2016 1 Document Information

More information

PUBLIC HEALTH SKILLS AND CAREER FRAMEWORK. Consultation

PUBLIC HEALTH SKILLS AND CAREER FRAMEWORK. Consultation PUBLIC HEALTH SKILLS AND CAREER FRAMEWORK Consultation 1 CONSULTATION GUIDANCE AND QUESTIONS Welcome to the public health skills and career framework. The framework is intended as a route map for public

More information